A Phase 3, Multicenter, Randomized, Open-Label, Comparator-Controlled Study to Assess Safety and Tolerability of Weekly TV-1106 Compared to Daily rhGH (dGH) in Adults With Growth Hormone-Deficiency
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Albusomatropin (Primary) ; Somatrogon
- Indications Somatotropin deficiency
- Focus Adverse reactions; Registrational
- Sponsors Teva Pharmaceutical Industries
- 26 Apr 2016 Status changed from active, no longer recruiting to discontinued due to a Business decision.
- 02 Mar 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 02 Mar 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2016 as per ClinicalTrials.gov record.